By Rob CurranKenvue, the Johnson & Johnson spinoff that makes Tylenol and Benadryl, said fourth-quarter net income fell slightly as a later start to flu season in 2023 complicated comparisons with a year earlier. The Skillman, N.J., drug maker posted fourth-quarter earnings of $327 million, or 17 cents a share, down from $361 million, or 21 cents a share, a year earlier.

Source: Wall Street Journal February 09, 2024 00:18 UTC